← Back to Clinical Trials
Recruiting NCT06484647

NCT06484647 Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06484647
Status Recruiting
Phase
Sponsor San Luigi Gonzaga Hospital
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 382 participants
Start Date 2024-06-01
Primary Completion 2024-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Percutaneous Coronary Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 382 participants in total. It began in 2024-06-01 with a primary completion date of 2024-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Nowadays, no studies compare the T-stenting And Minimal Protrusion (TAP) and External Minicrush techniques in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.

Eligibility Criteria

Inclusion Criteria: * Patients \>18 years of age * Patients with an indication for PCI, including chronic coronary syndrome and acute coronary syndromes (STEMI, NSTEMI, unstable angina) * Patients with at least one true coronary bifurcation according to the Medina classification 1.1.1, 0.1.1, 1.0.1, 0.0.1 Exclusion Criteria: * Patients who do not want or cannot sign the informed consent for the procedure. * Patients with severe peripheral vascular disease that limits vascular access to the point of making the procedure unsafe. * Patients with a life expectancy of \<1 year. * Patients with planned major surgery require prolonged discontinuation of antiplatelet therapy. * Pregnant women. * Patients who cannot take antiplatelet therapy for any reason.

Contact & Investigator

Central Contact

Giulio Piedimonte, MD

✉ giulio.piedimonte@gmail.com

📞 +393201764900

Frequently Asked Questions

Who can join the NCT06484647 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06484647 currently recruiting?

Yes, NCT06484647 is actively recruiting participants. Contact the research team at giulio.piedimonte@gmail.com for enrollment information.

Where is the NCT06484647 trial being conducted?

This trial is being conducted at Rivoli, Italy.

Who is sponsoring the NCT06484647 clinical trial?

NCT06484647 is sponsored by San Luigi Gonzaga Hospital. The trial plans to enroll 382 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology